Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 3/2016

01-06-2016 | RARE BONE DISEASE (CB LANGMAN AND E SHORE, SECTION EDITORS)

Hypophosphatasia

Authors: Agnès Linglart, Martin Biosse-Duplan

Published in: Current Osteoporosis Reports | Issue 3/2016

Login to get access

Abstract

Hypophosphatasia is a rare disorder due to a mutation in the ALPL gene encoding the alkaline phosphatase (ALP) leading to a diminished activity of the enzyme in bone, liver, and kidney. Hypophosphatasia is a heterogeneous disease, ranging from extreme life-threatening forms revealed at birth in young infants presenting with severely impaired bone mineralization, seizures, and hypercalcemia, to young adults with premature exfoliation of their teeth without any other symptom. We will review the challenges of the clinical, biochemical, radiological, and genetic diagnosis. Schematically, the diagnosis relies on low ALP levels and, in most cases, on the genetic defect in the ALPL gene. An enzyme replacement therapy is now developed for hypophosphatasia; early results in the severe form of the disease are extremely encouraging. However, multidisciplinary care remains the core of treatment of hypophosphatasia encompassing nutritional support, adjustment of calcium and phosphate intake, monitoring of vitamin D levels, careful and personalized physical therapy, and regular dental monitoring and care.
Literature
1.
2.
Millán JL. What can we learn about the neural functions of TNAP from studies on other organs and tissues? Subcell Biochem. 2015;76:155–66.CrossRefPubMed
3.
Whyte MP, Walkenhorst DA, Fedde KN, Henthorn PS, Hill CS. Hypophosphatasia: levels of bone alkaline phosphatase immunoreactivity in serum reflect disease severity. J Clin Endocrinol Metab. 1996;81:2142–8.PubMed
4.
Whyte MP. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci. 2010;1192:190–200.CrossRefPubMed
5.
Addison WN, Azari F, Sørensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem. 2007;282:15872–83.CrossRefPubMed
6.
Millán JL, Plotkin H. Hypophosphatasia—pathophysiology and treatment. Actual En Osteol. 2012;8:164–82.
7.
Waymire KG et al. Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat Genet. 1995;11:45–51.CrossRefPubMed
8.
Whyte MP et al. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5′-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest. 1995;95:1440–5.CrossRefPubMedPubMedCentral
9.
10.
Silva I, Castelão W, Mateus M, Branco JC. Childhood hypophosphatasia with myopathy: clinical report with recent update. Acta Reumatol Port. 2012;37:92–6.PubMed
11.
Weiss MJ et al. A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci U S A. 1988;85:7666–9.CrossRefPubMedPubMedCentral
12.
Taillandier A et al. Twelve novel mutations in the tissue-nonspecific alkaline phosphatase gene (ALPL) in patients with various forms of hypophosphatasia. Hum Mutat. 2001;18:83–4.CrossRefPubMed
13.•
14.
Watanabe A et al. Perinatal hypophosphatasia caused by uniparental isodisomy. Bone. 2014;60:93–7.CrossRefPubMed
15.
Lia-Baldini AS et al. A molecular approach to dominance in hypophosphatasia. Hum Genet. 2001;109:99–108.CrossRefPubMed
16.
Mornet E. Molecular genetics of hypophosphatasia and phenotype-genotype correlations. Subcell Biochem. 2015;76:25–43.CrossRefPubMed
17.
Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B. A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet. 2011;75:439–45.CrossRefPubMed
18.
McKiernan FE, Berg RL, Fuehrer J. Clinical and radiographic findings in adults with persistent hypophosphatasemia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2014;29:1651–60.CrossRef
19.
Mornet E, Hofmann C, Bloch-Zupan A, Girschick H, Le Merrer M. Clinical utility gene card for: hypophosphatasia - update 2013. Eur J Hum Genet EJHG. 2014;22. doi:10.​1038/​ejhg.​2013.​177.
20.
21.•
Whyte MP et al. Hypophosphatasia: validation and expansion of the Clinical Nosology for Children from 25 years experience with 173 pediatric patients. Bone. 2015. doi:10.​1016/​j.​bone.​2015.​02.​022. This article provides a large and complete phenotypic description of the largest cohort of patients affected with hypophosphatasia and a mutation in ALPL.
22.
Wenkert D et al. Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Res Off J Am Soc Bone Miner Res. 2011;26:2389–98.CrossRef
23.
Pauli RM, Modaff P, Sipes SL, Whyte MP. Mild hypophosphatasia mimicking severe osteogenesis imperfecta in utero: bent but not broken. Am J Med Genet. 1999;86:434–8.CrossRefPubMed
24.
Matsushita M, Kitoh H, Michigami T, Tachikawa K, Ishiguro N. Benign prenatal hypophosphatasia: a treatable disease not to be missed. Pediatr Radiol. 2014;44:340–3.CrossRefPubMed
25.•
Taketani T et al. Clinical and genetic aspects of hypophosphatasia in Japanese patients. Arch Dis Child. 2014;99:211–5. This article provides a large and complete phenotypic description of a large cohort of patients affected with hypophosphatasia and a mutation in ALPL. This description is confirmatory and complimentary to that of the group of M. Whyte.
26.
Sinico M et al. Specific osseous spurs in a lethal form of hypophosphatasia correlated with 3D prenatal ultrasonographic images. Prenat Diagn. 2007;27:222–7.CrossRefPubMed
27.
de Roo MGA et al. Infantile hypophosphatasia without bone deformities presenting with severe pyridoxine-resistant seizures. Mol Genet Metab. 2014;111:404–7.CrossRefPubMed
28.
Hofmann C et al. Compound heterozygosity of two functional null mutations in the ALPL gene associated with deleterious neurological outcome in an infant with hypophosphatasia. Bone. 2013;55:150–7.CrossRefPubMed
29.
Collmann H, Mornet E, Gattenlöhner S, Beck C, Girschick H. Neurosurgical aspects of childhood hypophosphatasia. Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg. 2009;25:217–23.CrossRef
30.
Plagmann HC, Kocher T, Kuhrau N, Caliebe A. Periodontal manifestation of hypophosphatasia. A family case report. J Clin Periodontol. 1994;21:710–6.CrossRefPubMed
31.
32.
33.
Lynch CD et al. Prosthodontic rehabilitation of hypophosphatasia using dental implants: a review of the literature and two case reports. J Oral Rehabil. 2009;36:462–8.CrossRefPubMed
34.
Lundgren T, Westphal O, Bolme P, Modéer T, Norén JG. Retrospective study of children with hypophosphatasia with reference to dental changes. Scand J Dent Res. 1991;99:357–64.PubMed
35.
Wendling D et al. Adult hypophosphatasia. Current aspects. Jt Bone Spine Rev Rhum. 2001;68:120–4.CrossRef
36.•
Berkseth KE et al. Clinical spectrum of hypophosphatasia diagnosed in adults. Bone. 2013;54:21–7. This article provides the first characterization of a cohort of hypophosphatasia in adults.
37.
Bianchi ML. Hypophosphatasia: an overview of the disease and its treatment. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2015. doi:10.​1007/​s00198-015-3272-1.
38.
Hofmann C et al. Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet EJHG. 2014;22:1160–4.CrossRefPubMed
39.
Whyte MP et al. Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure. J Clin Endocrinol Metab. 2013;98:4606–12.CrossRefPubMed
40.
Beck C, et al. Hypophosphatasia—recent advances in diagnosis and treatment. Open Bone J. 2009;1:8–15.
41.
Turan S et al. Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets. J Clin Res Pediatr Endocrinol. 2011;3:7–11.CrossRefPubMedPubMedCentral
42.
Caswell AM, Whyte MP, Russell RG. Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects. Crit Rev Clin Lab Sci. 1991;28:175–232.CrossRefPubMed
43.
44.
Girschick HJ, Schneider P, Kruse K, Huppertz HI. Bone metabolism and bone mineral density in childhood hypophosphatasia. Bone. 1999;25:361–7.CrossRefPubMed
45.
Chen H et al. Hypophosphatasia. Skeletal Radiol. 2013;42(295–296):317–8.CrossRef
46.
Guañabens N et al. Calcific periarthritis as the only clinical manifestation of hypophosphatasia in middle-aged sisters. J Bone Miner Res Off J Am Soc Bone Miner Res. 2014;29:929–34.CrossRef
47.
Beck C, Morbach H, Wirth C, Beer M, Girschick HJ. Whole-body MRI in the childhood form of hypophosphatasia. Rheumatol Int. 2011;31:1315–20.CrossRefPubMed
48.
Henthorn PS, Whyte MP. Infantile hypophosphatasia: successful prenatal assessment by testing for tissue-non-specific alkaline phosphatase isoenzyme gene mutations. Prenat Diagn. 1995;15:1001–6.CrossRefPubMed
49.
50.
51.
Wyckoff MH et al. Neonatal lethal osteochondrodysplasia with low serum levels of alkaline phosphatase and osteocalcin. J Clin Endocrinol Metab. 2005;90:1233–40.CrossRefPubMed
52.
Girschick HJ et al. Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia. Orphanet J Rare Dis. 2006;1:24.CrossRefPubMedPubMedCentral
53.
Drees P, Schmidt D, Lewens T, Vetter T, Meurer A. Hyperphosphatasia and hypophosphatasia in childhood. Orthop. 2008;37:31–9.CrossRef
54.
Sutton RAL, Mumm S, Coburn SP, Ericson KL, Whyte MP. ‘Atypical femoral fractures’ during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2012;27:987–94.CrossRef
55.
Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2009;24:1132–4.CrossRef
56.••
Millán JL et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2008;23:777–87. First demonstration that the recombinant alkaline phosphatase restores bone mineralization in an animal model of hypophosphatasia.
57.
Hofmann C et al. Recombinant enzyme replacement therapy in hypophosphatasia. Subcell Biochem. 2015;76:323–41.CrossRefPubMed
58.••
Whyte MP et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366:904–13. First and brilliant demonstration that the recombinant alkaline phosphatase improves life expectancy and restores bone mineralization in neonates with the severe form of hypophosphatasia.
59.
Katherine L Madson, Cheryl Rockman-Greenberg, Scott Moseley, Tatjana Odrljin & Michael P Whyte. Asfotase Alfa: Sustained Efficacy and Tolerability in Children with Hypophosphatasia Treated for 5 Years. ESPE Abstracts 2015;84 FC2.4.
Metadata
Title
Hypophosphatasia
Authors
Agnès Linglart
Martin Biosse-Duplan
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 3/2016
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-016-0309-0

Other articles of this Issue 3/2016

Current Osteoporosis Reports 3/2016 Go to the issue

Imaging (T Lang and F Wehrli, Section Editors)

The Role of Trunk Musculature in Osteoporotic Vertebral Fractures: Implications for Prediction, Prevention, and Management

Therapeutics and Medical Management (E Shane and R Adler, Section Editors)

The Skeletal Effects of Inhaled Glucocorticoids

Regenerative Biology and Medicine in Osteoporosis (T Webster, Section Editor)

Advances in Nanotechnology for the Treatment of Osteoporosis

Imaging (T Lang and F Wehrli, Section Editors)

Solid-State Quantitative 1H and 31P MRI of Cortical Bone in Humans